Tobacco-related cancers and prevention

Lung cancer mortality rates in men

Cancer prevention strategies face challenges in implementation, but the potential gains are striking. The dramatic declines in lung cancer incidence and mortality in many European countries after decreases in the prevalence of smoking are evidence of the power of successful prevention.

Lung cancer mortality and smoking prevalence in the UK (1950–2013) and Poland (1960–2013) and selected tobacco control interventions in the two countries

This figure shows that the mortality rate for lung cancer in men aged 30–79 years in the UK peaked in the early 1970s at about 160 per 100 000 per year and has since declined dramatically. In contrast, the lung cancer mortality rate in men in Poland only peaked two decades later; this can be partly attributed to the later commencement of the effective prevention of tobacco exposure through national control policy measures. In the UK, the first TV advertisement bans and health warnings on cigarette packs appeared in the early 1960s. In Poland, such initial measures were not taken until the late 1980s.

Sources

Thank you to Morena Sarzo of the International Agency for Research on Cancer (IARC/WHO) for designing and producing the figures.

  • IARC cancer mortality database, WHO Mortality Database (2016). Available from: http://www-dep.iarc.fr/WHOdb/WHOdb.htm (accessed 4 January 2018).
  • Cancer Research UK. Tobacco statistics. Available from: http://www.cancerresearchuk.org/healthprofessional/cancer-statistics/risk/tobacco#ref-3 (accessed 4 January 2018).
  • Zatoński WA, Przewoźniak K, Sulkowska U, Mańczuk M, Gumkowski J (2009). Palenie tytoniu w populacji mężczyzn i kobiet w Polsce w latach 1974-2004. Zeszyty Naukowe Ochrony Zdrowia, Zdrowie Publiczne i Zarządzanie. VII(2):4–11 [in Polish].
  • Berridge V, Loughlin K (2005). Smoking and the new health education in Britain 1950–1970s. Am J Public Health. 95(6):956–964.
  • Jassem J, Przewozniak K, Zatonski W (2014). Tobacco control in Poland-successes and challenges. Transl Lung Cancer Res. 3(5):280–285.